Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927464 | 0.84 | TSHR (0.46) | NPC1RAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL17324405 | 0.84 | KMT2A (0.50) | NPC1RAB9AALDH1A1KMT2APTGES | |
| SCHEMBL30091561 | 0.83 | DPP4 (0.38) | — | |
| SCHEMBL30091646 | 0.83 | ALOX15 (0.45) | PDE3BPDE3ANPC1RAB9AALDH1A1 | |
| SCHEMBL30091676 | 0.83 | KMT2A (0.38) | PDE3BPDE3ANPC1RAB9AALDH1A1 | |
| SCHEMBL23927454 | 0.83 | ALOX15 (0.45) | PDE3BPDE3ANPC1RAB9AALDH1A1 | |
| SCHEMBL23927442 | 0.83 | KMT2A (0.38) | PDE3BPDE3ANPC1RAB9AALDH1A1 | |
| SCHEMBL23927496 | 0.81 | KDM4E (0.40) | ALDH1A1HPGDKMT2AKDM4EGAA | |
| SCHEMBL23927502 | 0.80 | MMP2 (0.41) | NPC1RAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL23927468 | 0.80 | TSHR (0.43) | RAB9AALDH1A1HPGDKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | PDE3B 4066/4885PDE3A 3839/4885NPC1 2376/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | PDE3B 4066/4885PDE3A 3839/4885NPC1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.